terbutaline ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
bronchodilators, phenethylamine derivatives 2598 23031-25-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • terbutaline
  • bricaril
  • terbutalin
  • brican
  • terbutaline sulfate
  • terbutaline hemisulfate
A selective beta-2 adrenergic agonist used as a bronchodilator and tocolytic.
  • Molecular weight: 225.29
  • Formula: C12H19NO3
  • CLOGP: 0.48
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 4
  • TPSA: 72.72
  • ALOGS: -1.59
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2 mg Inhal.aerosol
2 mg Inhal.powder
20 mg Inhal.solution
15 mg O
15 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 213 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 56 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.11 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 14 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.50 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 3.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.75 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 15 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
March 25, 1974 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Asthma 233.90 16.65 170 8623 127391 63352838
Dyspnoea 114.23 16.65 269 8524 661044 62819185
Wheezing 98.00 16.65 91 8702 95504 63384725
Lactic acidosis 69.87 16.65 51 8742 38236 63441993
Acute kidney injury 58.57 16.65 119 8674 263296 63216933
Sleep disorder due to a general medical condition 55.20 16.65 29 8764 12159 63468070
Sputum discoloured 55.07 16.65 32 8761 16315 63463914
Middle insomnia 54.20 16.65 29 8764 12614 63467615
Nasal discharge discolouration 51.16 16.65 17 8776 2254 63477975
Squamous cell carcinoma of the oral cavity 44.49 16.65 10 8783 302 63479927
Full blood count abnormal 37.99 16.65 33 8760 31684 63448545
Allergy to metals 35.98 16.65 10 8783 725 63479504
Iodine allergy 35.09 16.65 10 8783 794 63479435
Shock haemorrhagic 35.00 16.65 20 8773 9875 63470354
Hyperlactacidaemia 32.84 16.65 13 8780 2836 63477393
Forced expiratory volume decreased 31.93 16.65 15 8778 4953 63475276
Fallopian tube disorder 30.77 16.65 8 8785 450 63479779
Heart rate increased 30.29 16.65 50 8743 94188 63386041
Cough 30.12 16.65 99 8694 292644 63187585
Obstructive airways disorder 29.89 16.65 24 8769 20675 63459554
Exposure during pregnancy 28.43 16.65 65 8728 155482 63324747
Productive cough 28.07 16.65 39 8754 63169 63417060
Hepatocellular injury 27.87 16.65 26 8767 27355 63452874
Tremor 27.26 16.65 58 8735 132181 63348048
Bronchospasm 27.02 16.65 21 8772 17259 63462970
Alopecia 26.55 16.65 7 8786 337529 63142700
Pleural rub 26.46 16.65 5 8788 62 63480167
Pneumonia 26.43 16.65 129 8664 456638 63023591
Lung diffusion disorder 25.90 16.65 5 8788 70 63480159
Eosinophilic granulomatosis with polyangiitis 25.26 16.65 10 8783 2182 63478047
Rubber sensitivity 24.66 16.65 10 8783 2321 63477908
Foetal exposure during pregnancy 24.49 16.65 26 8767 31936 63448293
Folate deficiency 24.08 16.65 10 8783 2465 63477764
Post viral fatigue syndrome 23.55 16.65 6 8787 311 63479918
Asthmatic crisis 23.47 16.65 9 8784 1804 63478425
Nasal congestion 22.67 16.65 36 8757 65624 63414605
Cholestasis 22.65 16.65 24 8769 29410 63450819
Toxic epidermal necrolysis 21.92 16.65 22 8771 25312 63454917
Smoke sensitivity 21.26 16.65 6 8787 460 63479769
Phlebectomy 20.78 16.65 4 8789 55 63480174
Joint swelling 20.33 16.65 10 8783 327656 63152573
Contraindicated product administered 20.26 16.65 3 8790 217645 63262584
Spirometry abnormal 20.08 16.65 5 8788 236 63479993
Eosinophil count abnormal 19.88 16.65 6 8787 582 63479647
Premature baby 19.79 16.65 19 8774 20716 63459513
Premature separation of placenta 19.74 16.65 8 8785 1853 63478376
Respiratory tract inflammation 19.72 16.65 6 8787 598 63479631
Neonatal respiratory distress syndrome 19.64 16.65 9 8784 2809 63477420
Haematoma 19.36 16.65 24 8769 34796 63445433
Forced expiratory volume abnormal 19.28 16.65 4 8789 82 63480147
Loss of personal independence in daily activities 19.27 16.65 42 8751 97248 63382981
Systemic lupus erythematosus 19.17 16.65 3 8790 208915 63271314
Allergy to animal 19.10 16.65 7 8786 1239 63478990
Exposure to allergen 18.52 16.65 5 8788 325 63479904
Eosinophilia 18.30 16.65 19 8774 22737 63457492
Respiratory distress 18.23 16.65 23 8770 33928 63446301
Respiratory rate increased 17.97 16.65 15 8778 13633 63466596
Chest discomfort 17.96 16.65 44 8749 109925 63370304
Tachycardia 17.96 16.65 46 8747 118110 63362119
Seasonal allergy 17.77 16.65 18 8775 20932 63459297
Renal tubular necrosis 17.63 16.65 14 8779 11864 63468365
Polyp 17.41 16.65 11 8782 6510 63473719
Therapeutic product effect incomplete 17.29 16.65 47 8746 125009 63355220
Hyperkinesia 16.97 16.65 7 8786 1697 63478532
Blood pressure increased 16.80 16.65 55 8738 162007 63318222

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Asthma 143.24 19.00 85 5068 42571 34909207
Wheezing 95.21 19.00 65 5088 41337 34910441
Blood immunoglobulin E increased 76.22 19.00 24 5129 2522 34949256
Cholestasis 65.94 19.00 44 5109 26904 34924874
Chest discomfort 62.93 19.00 57 5096 54473 34897305
Dyspnoea 59.55 19.00 154 4999 376628 34575150
Rhinitis 48.48 19.00 22 5131 6316 34945462
Hyperkaliuria 48.40 19.00 9 5144 95 34951683
Forced expiratory volume decreased 48.04 19.00 18 5135 3185 34948593
Obstructive airways disorder 47.05 19.00 29 5124 15465 34936313
Wolff-Parkinson-White syndrome 41.43 19.00 9 5144 217 34951561
Exposure during pregnancy 41.30 19.00 22 5131 8912 34942866
Agranulocytosis 37.94 19.00 30 5123 23791 34927987
Nasal disorder 37.00 19.00 13 5140 1915 34949863
Bronchospasm 34.92 19.00 21 5132 10710 34941068
Asthma-chronic obstructive pulmonary disease overlap syndrome 33.86 19.00 11 5142 1276 34950502
Toxic epidermal necrolysis 31.79 19.00 26 5127 21620 34930158
Gastrointestinal mucosal necrosis 31.61 19.00 7 5146 185 34951593
Sputum increased 30.80 19.00 12 5141 2358 34949420
Cough 27.34 19.00 65 5088 150075 34801703
Meralgia paraesthetica 27.26 19.00 6 5147 154 34951624
Placental transfusion syndrome 26.90 19.00 4 5149 8 34951770
Bronchospasm paradoxical 26.54 19.00 5 5148 57 34951721
Penile erythema 26.36 19.00 6 5147 180 34951598
Unmasking of previously unidentified disease 24.81 19.00 8 5145 906 34950872
Nasal inflammation 24.03 19.00 6 5147 269 34951509
Death 23.40 19.00 15 5138 398034 34553744
Foetal distress syndrome 23.36 19.00 8 5145 1092 34950686
Heart rate increased 22.77 19.00 31 5122 46312 34905466
Cyanosis 22.32 19.00 17 5136 12747 34939031
Prothrombin time ratio decreased 21.96 19.00 6 5147 383 34951395
Premature baby 21.58 19.00 20 5133 19613 34932165
Middle insomnia 21.33 19.00 13 5140 6789 34944989
Stillbirth 21.11 19.00 5 5148 179 34951599
Hepatic vein occlusion 21.06 19.00 5 5148 181 34951597
Respiratory distress 20.86 19.00 26 5127 35639 34916139
Subcapsular splenic haematoma 20.03 19.00 4 5149 63 34951715
Lung disorder 19.82 19.00 25 5128 34671 34917107
Ductus arteriosus premature closure 19.38 19.00 5 5148 256 34951522

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Asthma 248.70 14.98 192 12672 134903 79596621
Wheezing 158.32 14.98 139 12725 116525 79614999
Dyspnoea 122.78 14.98 358 12506 856667 78874857
Cholestasis 82.70 14.98 68 12796 52041 79679483
Forced expiratory volume decreased 76.04 14.98 33 12831 7781 79723743
Lactic acidosis 74.37 14.98 73 12791 70286 79661238
Obstructive airways disorder 67.26 14.98 49 12815 31410 79700114
Middle insomnia 66.67 14.98 38 12826 16031 79715493
Chest discomfort 62.40 14.98 93 12771 137951 79593573
Bronchospasm 58.38 14.98 41 12823 24818 79706706
Blood immunoglobulin E increased 57.76 14.98 25 12839 5857 79725667
Cough 56.74 14.98 158 12706 366631 79364893
Sputum discoloured 56.10 14.98 38 12826 21705 79709819
Heart rate increased 52.65 14.98 80 12784 120644 79610880
Toxic epidermal necrolysis 50.37 14.98 48 12816 44533 79686991
Shock haemorrhagic 44.59 14.98 32 12832 20028 79711496
Nasal discharge discolouration 43.17 14.98 16 12848 2505 79729019
Hyperkaliuria 42.76 14.98 9 12855 169 79731355
Productive cough 42.04 14.98 61 12803 88270 79643254
Acute kidney injury 41.79 14.98 180 12684 519224 79212300
Wolff-Parkinson-White syndrome 37.99 14.98 9 12855 294 79731230
Squamous cell carcinoma of the oral cavity 37.75 14.98 10 12854 518 79731006
Bronchospasm paradoxical 37.44 14.98 8 12856 162 79731362
Full blood count abnormal 37.28 14.98 39 12825 40435 79691089
Sleep disorder due to a general medical condition 36.94 14.98 25 12839 14252 79717272
Rhinitis 36.11 14.98 25 12839 14782 79716742
Nasal congestion 32.33 14.98 50 12814 76502 79655022
Hepatocellular injury 32.10 14.98 39 12825 47554 79683970
Eosinophilic granulomatosis with polyangiitis 30.92 14.98 14 12850 3646 79727878
Hyperlactacidaemia 30.91 14.98 16 12848 5579 79725945
Nasal disorder 30.53 14.98 14 12850 3755 79727769
Fallopian tube disorder 30.34 14.98 8 12856 407 79731117
Gastrointestinal mucosal necrosis 29.72 14.98 7 12857 223 79731301
Drug intolerance 29.20 14.98 4 12860 264115 79467409
Small intestinal haemorrhage 29.20 14.98 14 12850 4149 79727375
Agranulocytosis 27.33 14.98 35 12829 44995 79686529
Death 27.02 14.98 31 12833 566483 79165041
Penile erythema 26.80 14.98 6 12858 152 79731372
Haematoma 26.22 14.98 37 12827 52158 79679366
Respiratory distress 25.89 14.98 39 12825 58300 79673224
Pleural rub 25.48 14.98 5 12859 65 79731459
Blood pressure increased 25.03 14.98 83 12781 211277 79520247
Tremor 24.98 14.98 72 12792 170011 79561513
Sputum increased 24.94 14.98 13 12851 4600 79726924
Lung disorder 23.93 14.98 45 12819 80512 79651012
Bronchitis 23.91 14.98 60 12804 130584 79600940
Respiratory rate increased 23.91 14.98 23 12841 21577 79709947
Asthma-chronic obstructive pulmonary disease overlap syndrome 23.10 14.98 11 12853 3210 79728314
Smoke sensitivity 22.89 14.98 7 12857 609 79730915
Forced expiratory volume abnormal 22.28 14.98 5 12859 128 79731396
Post viral fatigue syndrome 22.07 14.98 6 12858 343 79731181
Alopecia 20.39 14.98 6 12858 231349 79500175
Lung diffusion disorder 20.35 14.98 5 12859 191 79731333
Increased bronchial secretion 19.79 14.98 10 12854 3317 79728207
Folate deficiency 19.70 14.98 10 12854 3350 79728174
Meralgia paraesthetica 19.64 14.98 6 12858 520 79731004
Hepatic vein occlusion 19.58 14.98 5 12859 224 79731300
Breath sounds abnormal 19.57 14.98 18 12846 15966 79715558
Sinus tachycardia 18.30 14.98 26 12838 36882 79694642
Asthmatic crisis 17.99 14.98 8 12856 1998 79729526
Systolic hypertension 17.88 14.98 6 12858 702 79730822
Urticaria 17.86 14.98 68 12796 185133 79546391
Unmasking of previously unidentified disease 17.80 14.98 8 12856 2049 79729475
Nasal inflammation 17.73 14.98 6 12858 721 79730803
Exposure to allergen 17.60 14.98 5 12859 336 79731188
Eosinophil count abnormal 17.54 14.98 6 12858 745 79730779
Decreased activity 17.36 14.98 13 12851 8681 79722843
Pneumonia 17.11 14.98 172 12692 660074 79071450
Allergy to animal 17.08 14.98 7 12857 1432 79730092
Joint swelling 17.02 14.98 13 12851 288633 79442891
Embolism arterial 16.72 14.98 7 12857 1511 79730013
Prothrombin time ratio decreased 16.32 14.98 6 12858 919 79730605
Cyanosis 15.95 14.98 20 12844 25162 79706362
Polyp 15.91 14.98 12 12852 8095 79723429
Eosinophilia 15.59 14.98 27 12837 45318 79686206
Dermatitis bullous 15.45 14.98 15 12849 14230 79717294
Rash maculo-papular 15.03 14.98 30 12834 56048 79675476

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC R03AC03 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Selective beta-2-adrenoreceptor agonists
ATC R03CC03 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS FOR SYSTEMIC USE
Selective beta-2-adrenoreceptor agonists
ATC R03CC53 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS FOR SYSTEMIC USE
Selective beta-2-adrenoreceptor agonists
MeSH PA D018663 Adrenergic Agents
MeSH PA D000322 Adrenergic Agonists
MeSH PA D058666 Adrenergic beta-2 Receptor Agonists
MeSH PA D000318 Adrenergic beta-Agonists
MeSH PA D018927 Anti-Asthmatic Agents
MeSH PA D001993 Bronchodilator Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D012102 Reproductive Control Agents
MeSH PA D019141 Respiratory System Agents
MeSH PA D013566 Sympathomimetics
MeSH PA D015149 Tocolytic Agents
CHEBI has role CHEBI:35522 beta-adrenergic agonists
CHEBI has role CHEBI:35523 bronchodilator
CHEBI has role CHEBI:35524 sympathomimetic
CHEBI has role CHEBI:35526 antidiabetic
CHEBI has role CHEBI:38462 acetylcholinesterase inhibitors
CHEBI has role CHEBI:49167 anti-asthmatic drugs
CHEBI has role CHEBI:66993 tocolytic drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Bronchitis indication 32398004 DOID:6132
Tear film insufficiency indication 46152009
Pulmonary emphysema indication 87433001
Asthma indication 195967001 DOID:2841
Skin irritation indication 367466007
Asthma management indication 406162001
Itching of skin indication 418363000
Acute exacerbation of asthma indication 708038006
Chronic Obstructive Pulmonary Disease with Bronchospasms indication
Minor Skin Wound Pain indication
Bronchospasm Prevention indication
Premature labor off-label use 6383007
Bronchiectasis off-label use 12295008 DOID:9563
Keratoconjunctivitis sicca off-label use 302896008 DOID:12895
Pulmonary edema contraindication 19242006 DOID:11396
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Hypokalemia contraindication 43339004
Conduction disorder of the heart contraindication 44808001
Ketoacidosis contraindication 56051008
Diabetes mellitus contraindication 73211009 DOID:9351
Compression of umbilical cord contraindication 79222000
Hyperglycemia contraindication 80394007 DOID:4195
Decreased respiratory function contraindication 80954004
Epilepsy contraindication 84757009 DOID:1826
Open wound contraindication 125643001
Seizure disorder contraindication 128613002
Chronic myocardial ischemia contraindication 413844008 DOID:3393
Myocardial ischemia contraindication 414795007 DOID:3393
Placental abruption contraindication 415105001
Denuded skin contraindication 418242004




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.48 acidic
pKa2 11.49 acidic
pKa3 12.74 acidic
pKa4 8.66 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Beta-2 adrenergic receptor GPCR AGONIST Ki 5.60 WOMBAT-PK CHEMBL
Beta-2 adrenergic receptor GPCR Kd 5.40 CHEMBL

External reference:

IDSource
4019941 VUID
N0000148026 NUI
D00688 KEGG_DRUG
23031-32-5 SECONDARY_CAS_RN
4018396 VANDF
4019941 VANDF
C0039542 UMLSCUI
CHEBI:9449 CHEBI
CHEMBL1760 ChEMBL_ID
DB00871 DRUGBANK_ID
CHEMBL1315867 ChEMBL_ID
CHEMBL1160544 ChEMBL_ID
D013726 MESH_DESCRIPTOR_UI
5403 PUBCHEM_CID
560 IUPHAR_LIGAND_ID
2616 INN_ID
N8ONU3L3PG UNII
10368 RXNORM
41721 MMSL
5548 MMSL
d00752 MMSL
001812 NDDF
004731 NDDF
24583009 SNOMEDCT_US
372745006 SNOMEDCT_US
45311002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
TERBUTALINE SULFATE HUMAN PRESCRIPTION DRUG LABEL 1 0115-2611 TABLET 2.50 mg ORAL ANDA 23 sections
TERBUTALINE SULFATE HUMAN PRESCRIPTION DRUG LABEL 1 0115-2622 TABLET 5 mg ORAL ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9375 INJECTION 1 mg SUBCUTANEOUS ANDA 22 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9375 INJECTION 1 mg SUBCUTANEOUS ANDA 22 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9746 INJECTION 1 mg SUBCUTANEOUS ANDA 22 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9746 INJECTION 1 mg SUBCUTANEOUS ANDA 22 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0404-9962 INJECTION, SOLUTION 1 mg SUBCUTANEOUS ANDA 11 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0404-9962 INJECTION, SOLUTION 1 mg SUBCUTANEOUS ANDA 11 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0404-9962 INJECTION, SOLUTION 1 mg SUBCUTANEOUS ANDA 11 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0527-1311 TABLET 5 mg ORAL ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0527-1311 TABLET 5 mg ORAL ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0527-1318 TABLET 2.50 mg ORAL ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0527-1318 TABLET 2.50 mg ORAL ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 10135-579 TABLET 2.50 mg ORAL ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 10135-580 TABLET 5 mg ORAL ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 10271-101 INJECTION 1 mg SUBCUTANEOUS ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 17478-933 INJECTION 1 mg SUBCUTANEOUS ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 21695-121 TABLET 5 mg ORAL ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 21695-122 TABLET 2.50 mg ORAL ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 24979-132 TABLET 2.50 mg ORAL ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 24979-132 TABLET 2.50 mg ORAL ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 24979-133 TABLET 5 mg ORAL ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 24979-133 TABLET 5 mg ORAL ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 52584-665 INJECTION, SOLUTION 1 mg SUBCUTANEOUS ANDA 11 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 52584-665 INJECTION, SOLUTION 1 mg SUBCUTANEOUS ANDA 11 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 53808-0312 TABLET 2.50 mg ORAL ANDA 22 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 62135-524 TABLET 2.50 mg ORAL ANDA 13 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 62135-525 TABLET 5 mg ORAL ANDA 13 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 62559-721 TABLET 2.50 mg ORAL NDA authorized generic 22 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 62559-722 TABLET 5 mg ORAL NDA authorized generic 22 sections